FDA Grants AP Status for Acetazolamide Sodium ANDA202693
The FDA has granted approval status (AP) for the Abbreviated New Drug Application (ANDA) 202693 for Acetazolamide Sodium submitted by Avet Lifesciences.
Therapeutic Area
Therapeutic area intelligence for Carbonic Anhydrase Inhibitor with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.